Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 16, 2013, Pages

  Magnani, Luca ^a,g   Stoeck, Alexander ^b   Zhang, Xiaoyang ^a   Lánczky, András ^c   Mirabella, Anne C ^a,g   Wang, Tian Li ^b   Gyorffy, Balázs ^c   Lupien, Mathieu ^a,d,e,f  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; NOTCH RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL GROWTH; CELL PROLIFERATION; CHROMATIN; CHROMATIN STRUCTURE; CONTROLLED STUDY; EPIGENETICS; GENE MAPPING; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; NUCLEAR REPROGRAMMING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY SEQUENCE; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE REGULATORY NETWORKS; HUMANS; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; MICROARRAY ANALYSIS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84876204394     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219992110     Document Type: Article

References (97)

1. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631-643.
2. Tyson JJ, et al. (2011) Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer 11(7):523-532.
3. Sørlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874.
4. van de Vijver MJ, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009.
5. Lupien M, et al. (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132(6):958-970.
6. Eeckhoute J, et al. (2009) Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers. Genome Res 19(3):372-380.
7. Magnani L, Ballantyne EB, Zhang X, Lupien M (2011) PBX1 genomic pioneer function drives ERa signaling underlying progression in breast cancer. PLoS Genet 7(11): e1002368.
8. Wang Q, et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2):245-256.
9. Carroll JS, et al. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122(1):33-43.
10. Laganière J, et al. (2005) From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA 102(33):11651-11656.
11. Holmes KA, et al. (2012) Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc Natl Acad Sci USA 109(8):2748-2753.
12. Tan SK, et al. (2011) AP-2y regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J 30(13):2569-2581.
13. Ali S, Buluwela L, Coombes RC (2011) Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med 62:217-232.
14. Davies C, et al.; Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378(9793):771-784.
15. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233-247.
16. Perey L, et al. (2007) Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 18(1):64-69.
17. Di Leo A, et al. (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594-4600.
18. Chia S, et al. (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 26(10):1664-1670.
19. Hajkova P (2010) Epigenetic reprogramming-taking a lesson from the embryo. Curr Opin Cell Biol 22(3):342-350.
20. Heintzman ND, et al. (2009) Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459(7243):108-112.
21. Heinz S, et al. (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38(4):576-589.
22. Rodríguez-Ubreva J, et al. (2012) Pre-B cell to macrophage transdifferentiation without significant promoter DNA methylation changes. Nucleic Acids Res 40(5): 1954-1968.
23. Wang KC, et al. (2011) A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472(7341):120-124.
24. Santen RJ, et al. (2008) Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 630:19-34.
25. Chan CMW, Martin L-A, Johnston SRD, Ali S, Dowsett M (2002) Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81(4-5):333-341.
26. Brodie A, et al. (2005) Model systems: Mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol 95(1-5):41-48.
27. Aguilar H, et al. (2010) Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 29(45):6071-6083.
28. Miller WR, Larionov A (2010) Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res 12(4):R52.
29. Haughian JM, et al. (2011) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci USA 109(8):2742-2747.
30. Jeng MH, et al. (1998) Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139(10):4164-4174.
31. Song RX, et al. (2002) Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 193(1-2):29-42.
32. Martin L-A, et al. (2011) An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids 76(8):772-776.
33. Strahl BD, et al. (2002) Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. Mol Cell Biol 22(5):1298-1306.
34. Bannister AJ, et al. (2005) Spatial distribution of di-and tri-methyl lysine 36 of histone H3 at active genes. J Biol Chem 280(18):17732-17736.
35. Pokholok DK, et al. (2005) Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122(4):517-527.
36. Lupien M, et al. (2010) Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 24(19):2219-2227.
37. Contesso G, et al. (1987) The importance of histologic grade in long-term prognosis of breast cancer: A study of 1, 010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5(9):1378-1386.
38. Chen S-T, et al. (2011) Correlation of histologic grade with other clinicopathological parameters, intrinsic subtype, and patients' clinical outcome in Taiwanese women. Jpn J Clin Oncol 41(12):1327-1335.
39. Sabo PJ, et al. (2004) Discovery of functional noncoding elements by digital analysis of chromatin structure. Proc Natl Acad Sci USA 101(48):16837-16842.
40. Birney E, et al.; ENCODE Project Consortium; NISC Comparative Sequencing Program; Baylor College of Medicine Human Genome Sequencing Center; Washington University Genome Sequencing Center; Broad Institute; Children's Hospital Oakland Research Institute (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447(7146):799-816.
41. Lee TI, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125(2):301-313.
42. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA (2007) A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130(1):77-88.
43. Heintzman ND, et al. (2007) Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 39(3):311-318.
44. Visel A, et al. (2009) ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 457(7231):854-858.
45. Ernst J, Kellis M (2010) Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol 28(8):817-825.
46. Ernst J, et al. (2011) Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473(7345):43-49.
47. Rada-Iglesias A, et al. (2011) A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470(7333):279-283.
48. Zentner GE, Tesar PJ, Scacheri PC (2011) Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res 21(8):1273-1283.
49. Giresi PG, Kim J, McDaniell RM, Iyer VR, Lieb JD (2007) FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res 17(6):877-885.
50. Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3(1):85-94.
51. Gutierrez MC, et al. (2005) Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23(11):2469-2476.
52. He HH, et al. (2012) Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res 22(6):1015-1025.
53. Schmidt D, et al. (2010) A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res 20(5):578-588.
54. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43(1): 27-33.
55. Ross-Innes CS, et al. (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381):389-393.
56. Fasco MJ, Amin A, Pentecost BT, Yang Y, Gierthy JF (2003) Phenotypic changes in MCF-7 cells during prolonged exposure to tamoxifen. Mol Cell Endocrinol 206(1-2): 33-47.
57. Sanchez CG, et al. (2011) Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13(2):R21.
58. Bourdeau V, et al. (2008) Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells. Nucleic Acids Res 36(1):76-93.
59. Sengupta S, Sharma CGN, Jordan VC (2010) Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig 2(2):235-243.
60. Fan M, et al. (2006) Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66(24):11954-11966.
61. McLean CY, et al. (2010) GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 28(5):495-501.
62. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M (2004) The KEGG resource for deciphering the genome. Nucleic Acids Res 32(Database issue):D277-D280.
63. Bray SJ (2006) Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol 7(9):678-689.
64. Györffy B, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res Treat 123(3):725-731.
65. Kiba T, et al. (2008) The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery. BMC Cancer 8:323.
66. Park S, et al. (2012) Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21(1):50-57.
67. Park JT, Shih IeM, Wang T-L (2008) Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res 68(21):8852-8860.
68. Goudet G, Delhalle S, Biemar F, Martial JA, Peers B (1999) Functional and cooperative interactions between the homeodomain PDX1, Pbx, and Prep1 factors on the somatostatin promoter. J Biol Chem 274(7):4067-4073.
69. Wolfe MS (2006) The gamma-secretase complex: Membrane-embedded proteolytic ensemble. Biochemistry 45(26):7931-7939.
70. Konishi J, et al. (2007) Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67(17):8051-8057.
71. Watters JW, et al. (2009) De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res 69(23):8949-8957.
72. Sotiriou C, et al. (2006) Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4): 262-272.
73. Hoskins JM, Carey LA, McLeod HL (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9(8):576-586.
74. Schiff R, et al. (2000) Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 92(23):1926-1934.
75. Shou J, et al. (2004) Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12): 926-935.
76. Hurtado A, et al. (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456(7222):663-666.
77. Ellis MJ, et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353-360.
78. Flanagan JM, et al. (2009) Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets. Mol Cancer Ther 8(1):249-260.
79. Stegmaier K, et al. (2004) Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet 36(3):257-263.
80. van't Veer LJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530-536.
81. Sørlie T, et al. (2010) The importance of gene-centring microarray data. Lancet Oncol 11(8):719-720, author reply 720-721.
82. Akhtar-Zaidi B, et al. (2012) Epigenomic enhancer profiling defines a signature of colon cancer. Science 336(6082):736-739.
83. Creighton CJ, et al. (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68(18):7493-7501.
84. Coser KR, et al. (2009) Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA 106(34):14536-14541.
85. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AMH (2005) Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 65(12):5439-5444.
86. Howell A, et al. (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 22(9):1605-1613.
87. Miller TW, et al. (2011) ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338-351.
88. Gozgit JM, et al. (2007) PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. Br J Cancer 97(6): 809-817.
89. Howell A, et al. (2002) Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20(16):3396-3403.
90. Muellner MK, et al. (2011) A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol 7(11):787-793.
91. Efferson CL, et al. (2010) Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 70(6):2476-2484.
92. Rizzo P, et al. (2008) Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68(13):5226-5235.
93. Pan L, Glenn ST, Jones CA, Gross KW (2005) Activation of the rat renin promoter by HOXD10.PBX1b.PREP1, Ets-1, and the intracellular domain of notch. J Biol Chem 280(21):20860-20866.
94. Ji T, Lee M, Pruitt SC, Hangauer DG (2004) Privileged scaffolds for blocking proteinprotein interactions: 1, 4-disubstituted naphthalene antagonists of transcription factor complex HOX-PBX/DNA. Bioorg Med Chem Lett 14(15):3875-3879.
95. Aulisa L, Forraz N, McGuckin C, Hartgerink JD (2009) Inhibition of cancer cell proliferation by designed peptide amphiphiles. Acta Biomater 5(3):842-853.
96. Hebenstreit D, et al. (2011) EpiChIP: Gene-by-gene quantification of epigenetic modification levels. Nucleic Acids Res 39(5):e27.
97. Blankenberg D, et al. (2010) Galaxy: A web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol Chapter 19:Unit 19.10.1-19.10.21.